Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML-Reference-Cited by-同舟云学术

Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML

Published:2013-04-15 Issue:11 Volume:27 Page:2157-2164
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Nomdedéu J F, ,Hoyos M,Carricondo M,Bussaglia E,Estivill C,Esteve J,Tormo M,Duarte R,Salamero O,de Llano M P Q,García A,Bargay J,Heras I,Martí-Tutusaus J M,Llorente A,Ribera J M,Gallardo D,Aventin A,Brunet S,Sierra J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2013111.pdf

Reference36 articles.

1. Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012; 119: 332–341.

2. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115–2121.

3. Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003; 21: 1988–1995.

4. Cilloni D, Messa F, Martinelli G, Gottardi E, Arruga F, Defilippi I et al. WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. Leukemia 2007; 21: 1442–1450.

5. Chau YY, Hastie ND . The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis. Trends Genet 2012; 28: 515–524.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia;British Journal of Haematology;2024-08-27

2. Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia;Frontiers in Oncology;2024-04-24

3. WT1 and TP53 as valuable diagnostic biomarkers for relapse after hematopoietic stem cell transplantation in acute myeloid leukemia;Molecular Biology Reports;2024-02-01

4. Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia;Clinical Interventions in Aging;2023-06

5. Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing;JCO Precision Oncology;2023-04